Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Overview of attention for article published in BMC Neurology, July 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 1,633 followers.

Drug-associated side effects are a major driver for prescribing glatiramer acetate for #MS https://t.co/6sWDwHTAga . Please retweet or share, and visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content! https://t.co/7CGnLMiP3i

17 Aug 2019

Reply Repost Favourite

RT @ingentium_ms: Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatm…

15 Jul 2019

Reply Repost Favourite

Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss #MS #MultipleSclerosis patients. https://t.co/CjUIoVc9t8

15 Jul 2019

Reply Repost Favourite

New NNT→Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients. https://t.co/JWgPZoEBg5

14 Jul 2019

Reply Repost Favourite